EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma

Blood

Volumn 128, Issue 7, 2016, Pages 948-958

  Yan, Junli ^a   Li, Boheng ^b   Lin, Baohong ^c   Lee, Pei Tsung ^a   Chung, Tae Hoon ^a   Tan, Joy ^a   Bi, Chonglei ^a   Lee, Xue Ting ^a   Selvarajan, Viknesvaran ^d   Ng, Siok Bian ^a,b,d   Yang, Henry ^a   Yu, Qiang ^e   Chng, Wee Joo ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c National University Cancer Institute   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE METHYLTRANSFERASE; INTERLEUKIN 2; JANUS KINASE 3; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2; EED PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE; JAK3 PROTEIN, HUMAN; LYSINE; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN SUBUNIT; RNA POLYMERASE II; SUZ12 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; DNA REPLICATION; ECTOPIC EXPRESSION; GENE ACTIVATION; GENE EXPRESSION; HISTONE METHYLATION; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; BIOLOGICAL MODEL; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHYLATION; NATURAL KILLER T CELL; PATHOLOGY; PHOSPHORYLATION; PROTEIN SUBUNIT; T CELL LYMPHOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; JANUS KINASE 3; LYMPHOMA, T-CELL; LYSINE; METHYLATION; MODELS, BIOLOGICAL; NATURAL KILLER T-CELLS; PHOSPHORYLATION; PHOSPHOTYROSINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS; RNA POLYMERASE II;

EID: 85010008853     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-690701     Document Type: Article

References (35)

1. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA. 2012; 109(52):21360-21365.
2. Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9(10): 643-650.
3. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007;27(14):5105-5119.
4. Lee ST, Li Z, Wu Z, et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell. 2011;43(5): 798-810.
5. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338(6113):1465-1469.
6. Yan J, Ng SB, Tay JL, et al. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity. Blood. 2013;121(22): 4512-4520.
7. Gonzalez ME, Moore HM, Li X, et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci USA. 2014;111(8):3098-3103.
8. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7): 591-597.
9. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasaltype natural killer cell lymphoma. Leukemia. 2014; 28(2):338-348.
10. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302(5646):875-878.
11. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation. 2005;80(9):1283-1292.
12. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors [published correction appears in Blood. 2009;114(14):3132]. Blood. 2008;111(4):2155-2157.
13. Steele AJ, Prentice AG, Cwynarski K, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood. 2010;116(22):4569-4577.
14. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011;223(4):496-510.
15. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890-896.
16. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
17. Jung HY, Jun S, Lee M, et al. PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol Cell. 2013;52(2):193-205.
18. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47(9): 701-706.
19. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005; 310(5746):306-310.
20. Wei Y, Chen YH, Li LY, et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011;13(1):87-94.
21. Lee S, Park HY, Kang SY, et al. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. Oncotarget. 2015;6(19):17764-17776.
22. Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013; 23(6):839-852.
23. Chen S, Bohrer LR, Rai AN, et al. Cyclindependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol. 2010;12(11):1108-1114.
24. Kaneko S, Li G, Son J, et al. Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev. 2010;24(23):2615-2620.
25. Wu SC, Zhang Y. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J Biol Chem. 2011;286(32):28511-28519.
26. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS. Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCPmediated degradation. Oncogene. 2015;34(4): 445-454.
27. Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857-861.
28. Bender S, Tang Y, Lindroth AM, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013; 24(5):660-672.
29. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
30. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-726.
31. Ntziachristos P, Tsirigos A, Van Vlierberghe P, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. 2012;18(2):298-301.
32. Lin Q, Lai R, Chirieac LR, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005; 167(4):969-980.
33. Ye Q, Kantonen S, Gomez-Cambronero J. Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J Mol Biol. 2013; 425(4):755-766.
34. Henkels KM, Farkaly T, Mahankali M, Segall JE, Gomez-Cambronero J. Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3). J Mol Biol. 2011;408(5):850-862.
35. Ye Q, Kantonen S, Henkels KM, Gomez-Cambronero J. A new signaling pathway (JAK-Fesphospholipase D) that is enhanced in highly proliferative breast cancer cells. J Biol Chem. 2013;288(14):9881-9891.